DOTATATE PET/MR Imaging Differentiates Secondary-Progressive from de Novo World Health Organization Grade 3 Meningiomas.
Jun 7, 2024DOI: 10.3174/ajnr.a8219Journal ArticleAJNR
Written by: Joon Tae KimSe Jung Chris ChangArsalan HaghdelRohan R RamakrishnaSusan C PannulloTheodore H SchwartzJoseph R OsborneRajiv S MaggeHoward A FineBabacar CissePhilip StiegEaton LinMichelle RoytmanJoshua D PalmerNicolas A KarakatsanisDavid PisapiaBenjamin LiechtyJonathan P S KniselyJana Ivanidze
Find these authors on Roon
RR
Dr. Rohan Ramakrishna
Brain & Spinal Tumor · WCM
RM
Dr. Rajiv Magge
Neuro Oncology · NYP Weill Cornell
Summary
BACKGROUND AND PURPOSE: WHO grade 3 meningiomas are rare and poorly understood and have a higher propensity for recurrence, metastasis, and worsened clinical outcomes compared with lower-grade meningiomas. The purpose of our study was to prospectively evaluate the molecular profile, PET characteristics, and outcomes of patients with World Health Organization grade 3 meningiomas who were imaged with gallium 68 (68Ga) DOTATATE PET/MR imaging.MATERIALS AND METHODS: Patients with World Health Organization grade 3 meningiomas enrolled in our prospective observational cohort evaluating the utility of (68Ga) DOTATATE PET/MR imaging in somatostatin receptor positive brain tumors were included. We stratified patients by de novo-versus-secondary-progressive status and evaluated the differences in the PET standard uptake value, molecular profiles, and clinical outcomes.RESULTS: Patients met the inclusion criteria (secondary-progressive: 7/14; de novo: 7/14). The secondary-progressive cohort had a significantly higher per-patient number of surgeries (4.1 versus 1.6; P= .011) and trended toward a higher number of radiation therapy courses (2.4 versus 1.6; P= .23) and cumulative radiation therapy doses (106Gy versus 68.3Gy; P= .31). The secondary-progressive cohort had a significantly lower progression-free survival compared with the de novo cohort (4.8 versus 37.7 months; P= .004). Secondary-progressive tumors had distinct molecular pathology profiles with higher numbers of mutations (3.5 versus 1.2; P= .024). Secondary-progressive tumors demonstrated higher PET standard uptake values (17.1 versus 12.4; P= .0021).CONCLUSIONS: Our study confirms prior work illustrating distinct clinical outcomes in secondary-progressive and de novo World Health Organization grade 3 meningiomas. Furthermore, our findings support (68Ga) DOTATATE PET/MR imaging as a useful management strategy in World Health Organization grade 3 meningiomas and provide insight into meningioma biology, as well as clinical management implications.
RM
Dr. Rajiv Magge
Neurology · Neuro OncologyNewYork–Presbyterian HospitaldrrajivmaggeNew York, NY